Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip J Monaghan

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
JNCI Cancer Spectrum|November 22, 2019
Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration RateEdward H Williams, Claire M Connell, James M J Weaver, et al.
Eclinicalmedicine|June 24, 2026
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UKRobert D Morgan, Catharine Porter, Cong Zhou, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
JNCI Cancer Spectrum|November 22, 2019
Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration RateEdward H Williams, Claire M Connell, James M J Weaver, et al.
Eclinicalmedicine|June 24, 2026
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UKRobert D Morgan, Catharine Porter, Cong Zhou, et al.
Pageof 4